Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by Allergy & Asthma Medical Group & Research Center.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Allergy & Asthma Medical Group & Research Center
ClinicalTrials.gov Identifier:
NCT00235053
First received: October 6, 2005
Last updated: January 30, 2006
Last verified: September 2005

October 6, 2005
January 30, 2006
August 2005
Not Provided
To determine the magnitude of change from baseline to end of study in the Voice Handicap Index (VHI) with Advair® DISKUS 250/50 mcg BID in subjects with mild persistent asthma.
Same as current
Complete list of historical versions of study NCT00235053 on ClinicalTrials.gov Archive Site
  • 1. Voice Related Quality of Life (VRQOL)
  • 2. Inhaled Corticosteroid Questionnaire (ICQ)
  • 3. Reflux Symptom Index (RSI)
  • 4. Videostroboscopy and Determination of Reflux Finding Score (RFS)
  • 5. Voice jitter
  • 6. Voice shimmer
  • 7. Signal to noise ratio
  • 8. Oropharyngeal Candida species culture
  • 9. Oropharyngeal Candida species related symptoms
  • 10. Oropharyngeal thrush on physical exam
Same as current
Not Provided
Not Provided
 
Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID
A Pilot Study to Assess the Incidence of Local Oropharyngeal and Laryngeal Adverse Effects of Advair DISKUS 250/50 Mcg BID as Assessed by the Development of Laryngitis and Oropharyngeal Candidiasis in Adults With Mild Persistent Asthma

This Pilot study is designed to explore the rate of local side effects of fluticasone as delivered by Advair and to determine the best outcome measure to assess these effects. This study is the initial step, and will be followed by a larger scale study.

Asthma is a chronic inflammatory disorder of the airways. The inflammation is associated with bronchial hyperresponsiveness, airflow obstruction, and respiratory symptoms including wheezing, coughing and chest tightness.

Inhaled corticosteroids are the most effective controller asthma medications. They are indicated for management of persistent asthma at all levels of severity. They have been documented to improve symptoms and pulmonary function and reduce exacerbations, need for quick-relief medications and airway hyperresponsiveness.

Despite their benefits, inhaled corticosteroids have been associated with adverse local effects. These include oral candidiasis and dysphonia. However, though these risks have been reported, they have not been carefully studied. The incidence of oral candidiasis in newly treated subjects and its onset within a carefully monitored timeframe have not been adequately assessed.

A more overtly undesirable effect is dysphonia. Data on it are usually collected from spontaneous reports by patients in clinical trials. However, awareness of dysphonia requires a certain degree of subjective discomfort to initiate the report. Subjective awareness of dysphonia often varies based on an individuals voice requirements. A singer, for example, is usually acutely aware of minor voice changes in contrast to someone who does not depend on voice quality. Nonetheless, voice abnormalities can probably occur with similar frequency in patients who are concerned or not concerned with their voice due to inhaled corticosteroids. New subjective scales for reporting on an individual’s voice have recently been validated and published in other areas. These scales have not been validated in patients with asthma or in subjects using inhaled corticosteroids. New technologies for objective voice assessment have also been developed and these permit greater ability to quantify voice changes. These advances permit better measures of the potential adverse effects of inhaled corticosteroids on voice both with regard to onset of abnormalities and with regard to magnitude of effects.

This pilot study is an initial probe into clarifying the potential of the inhaled corticosteroid, fluticasone propionate delivered in the Advair DISKUS device to produce oral candidiasis and voice changes, and to determine the best measurement to quantitate objectively that effect.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Asthma
  • Candidiasis, Oral
  • Voice Disorders
Drug: fluticasone/salmeterol DISKUS 250/50
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
13
November 2005
Not Provided

Inclusion Criteria:

  1. Male or Female, 18-55 years of age. Females will be eligible only if they are:

    1. Surgically sterilized, post-menopausal, abstinent, or practicing adequate method of birth control, and if they have a
    2. Negative urine pregnancy test (females of childbearing potential)
  2. History of mild persistent asthma for at least 6 months as defined by NIH NHLBI April 19971

At Visit 1 (Screening) treatment for the last 30 days prior to screening must be:

  • No inhaled corticosteroid therapy. (Previous use of leukotriene receptor antagonists, and/or cromones, in addition to bronchodilators also allowed.)

Exclusion Criteria:

  1. Female subjects who are pregnant or trying to become pregnant
  2. Breast feeding
  3. Current patient reported hoarseness or sore throat
  4. Presence of oropharyngeal thrush (as determined by investigator examination without culture results)
  5. Unresolved fungal, viral or bacterial infection elsewhere in the body
  6. Viral or bacterial respiratory tract infection within the last 14 days
  7. History of persistent gastro-esophageal reflux refractory to conventional treatment within the last 30 days
  8. Has smoked within the previous 6 months or has greater than a lifetime 10 pack-year smoking history or regular exposure to environmental tobacco smoke
  9. History of inflammatory arthritis requiring immunosuppressive or corticosteroid therapy
  10. History of glaucoma, cataracts (lens opacities), retinal disease, or blindness
  11. Any serious concomitant disease such as cancer or serious renal, hepatic, cardiac, immunodeficiency, neurological, psychiatric, or other disease
  12. Any medical condition that, in the judgment of the investigator, might interfere with the study, require treatment or make implementation of the protocol or interpretation of the study results difficult
  13. Active or quiescent tuberculosis infections of the respiratory tract
  14. History of chronic bronchitis, COPD or emphysema
  15. History of alcohol abuse (more than 2 drinks/day on average) or drug abuse within the past 2 years
  16. History within the last 2 years of moderate asthma requiring prednisone on more than two occasions per year
  17. Treatment with any investigational drug within the past 30 days
  18. More than 1 short (less than 2 weeks) course of systemic corticosteroids in the previous year prior to screening (Visit 1) or have had systemic corticosteroids in the past pervious 2 months prior to Visit 1.
  19. Subjects can be on maintenance immunotherapy but cannot have begun an immunotherapy regimen or have had a change in their immunotherapy regimen within 30 days prior to screening (Visit 1).
  20. Subjects may be on intranasal steroid if it has been maintained for 4 weeks prior to screen and a constant stable dose is maintained for the duration of the trial.
Both
18 Years to 55 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00235053
NONE0-L00081
Not Provided
Not Provided
Allergy & Asthma Medical Group & Research Center
Not Provided
Principal Investigator: Eli O Meltzer, MD Allergy & Asthma Medical Group & Research Center
Allergy & Asthma Medical Group & Research Center
September 2005

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP